Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

(2015) Frederik B. Thomsen et al.   EUROPEAN JOURNAL OF CANCER

Poor association between the progression criteria in active surveillance and subsequent histopathological findings following radical prostatectomy

(2015) Frederik Birkebæk Thomsen et al.   Scandinavian Journal of Urology

Active surveillance for clinically localized prostate cancer--A systematic review

(2014) Frederik B. Thomsen et al.   JOURNAL OF SURGICAL ONCOLOGY

Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer

(2013) Frederik Birkebaek Thomsen et al.   BJU INTERNATIONAL

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

(2013) Axel Heidenreich et al.   EUROPEAN UROLOGY

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

(2013) Paul Blanche et al.   STATISTICS IN MEDICINE

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively

(2010) M. Frank O'Brien et al.   INTERNATIONAL JOURNAL OF CANCER

Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort

(2009) Andrew J. Vickers et al.   EUROPEAN UROLOGY

PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging

(2008) Stacy Loeb et al.   EUROPEAN UROLOGY

Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer

(2008) Andrew J. Vickers et al.   JOURNAL OF CLINICAL ONCOLOGY